Aligos Signs a Research Collaboration and Development Agreement with Amoytop to Discover and Develop Oligonucleotides for Liver Diseases
Shots:
- Aligos will receive an up front and research collaboration funding and will be eligible to receive development and sales milestones of ~$109M for licensed products along with royalties on net sales. The companies collaborated to research and develop oligonucleotide compounds for the treatment of liver disease
- Amoytop to get an option to obtain an exclusive license for the development and commercialization of the resultant products in the Greater China territory while Aligos will retain rights in the rest-of-world
- The collaboration will leverage Aligos’ oligonucleotide platform to discover and develop novel candidates for liver diseases in China
Ref: Aligos | Image: Aligos
Related News:- Aligos Discontinues ALG-020572 in the (ALG-020572-401) Study for the Treatment of Chronic Hepatitis B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
